The European Medicines Agency (EMA) says it has been hit by a cyber-attack and documents relating to a Covid-19 vaccine have been accessed. BioNTech, which makes one of the vaccines in partnership with Pfizer, said its regulatory submission was accessed during the attack. The EMA is working on approval of two Covid-19 vaccines, which it expects to conclude within weeks. The cyber-attack was not expected to impact that timeline, BioNTech said. The EMA did not provide any details on the nature of the cyber-attack in a brief statement on its website, beyond saying a full investigation had been launched. A spokesperson for the agency said it was still "functional". But BioNTech, in a statement published on its website, said it had been told its documents had been accessed. "Today, we were informed... that the agency has been subject to a cyber-attack and that some documents relating to the regulatory submission for Pfizer and BioNTech's Covid-19 vaccine candidate, BNT162b2, which has been stored on an EMA server, had been unlawfully accessed," it said. "EMA has assured us that the cyber-attack will have no impact on the timeline for its review," it added. It said it had made the details of the hack public "given the critical public health considerations and the importance of transparency". And it also said it was "unaware" of any personal data of participants in its medical studies being compromised. The EMA authorises the use of medicines across the European Union. It is trying to decide if the Pfizer/BioNTech jab - which has just begun being rolled out in the UK - and another made by Moderna are safe for use in EU countries. It is not clear if the Moderna documents have also been accessed. The cyber-attack is the latest in a string of attacks and warnings about hacking threats against vaccine-makers and public health bodies. Allergy warning over Covid vaccine Rich countries 'hoarding Covid vaccines' The use of cyber-attacks against bodies involved in the vaccine rollout has been a feature of recent months. Security services warned in the summer that Russian intelligence had been targeting organisations attempting to develop a successful vaccine. In October, a pharmaceutical company based in India was the victim of a significant cyber-attack. And in recent days, IBM said the cold storage supply chain used to transport viable vaccines had come under cyber-attack - probably by a nation state. The cyber-attack comes the day before the agency is due to update the European Parliament on the progress of the vaccine assessments. Euro-MPs on the Public Health Committee are due to quiz the agency's executive director "on how close the most advanced vaccines are to receiving authorisation" on Thursday. The UK's National Cyber Security Centre, meanwhile, said there was no indication the cyber-attack would affect the rollout of the vaccine in the UK. "We are working with international partners to understand the impact of this incident affecting the EU's medicine regulator, but there is currently no evidence to suggest that the UK's medicine regulator has been affected," it said. Source: https://www.bbc.com/news/technology-55249353
ICS Legal : UK Immigration Advice | UK Visas | Partners & Marriage Visas | Tier 1 Start-up, Tier 1 Innovator & Tier 1 Investor Visas | British Citizenship. ICS Legal is part of ICS Legal Immigration Specialists Ltd. The content and the source codes contained in this page and subsequent pages of www.icslegal.com are the property of ICS Legal Immigration Specialists Ltd. Company Reg Company No. 08703375. Company Registered in England & Wales. By logging into the site, you have accepted our terms and conditions and must abide accordingly. Unauthorised reproduction and copying is strictly prohibited. Selective contents of the website have been re-produced in accordance to Office of Public Sector Information (OPSI). ICS Legal Immigration Specialists Ltd holds PSI Licence and licence number is C2009002244. Parliamentary Licence number is P2009000241.
The content on our site is provided for general information only. It is not intended to amount to advice on which you should rely. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Although we make reasonable efforts to update the information on our site, we make no representations, warranties or guarantees, whether express or implied, that the content on our site is accurate, complete or up-to-date. We do not guarantee that our site, or any content on it, will always be available or be uninterrupted. Access to our site is permitted on a temporary basis. We may suspend, withdraw, discontinue or change all or any part of our site without notice. We will not be liable to you if for any reason our site is unavailable at any time or for any period. You are responsible for making all arrangements necessary for you to have access to our site. You are also responsible for ensuring that all persons who access our site through your Internet connection are aware of these terms, and that they comply with them.
We have placed cookies on your device to enable the website to function and to help improve the website. Please read on to learn about how
to control cookies. Some of the cookies we use are essential for the website to work. We also use some non-essential cookies to collect
information to make reports and help us improve the site. To control non-essential third party cookies you can adjust your browser settings.